242MO Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of four prospective multicentric studies
Federica Miglietta(Peter MacCallum Cancer Centre), Valentina Guarneri(Istituto Oncologico Veneto), Gian Luca De Salvo(Istituto Oncologico Veneto), Laura Merlini(Azienda Ospedale - Università Padova), Fable Zustovich, Emilio Bria(Università Cattolica del Sacro Cuore), Alberto Zambelli, Grazia Arpino(University of Naples Federico II), Vittoria Fotia(Ospedale Papa Giovanni XXIII), Carlo Tondini(Ospedale Papa Giovanni XXIII), Tommaso Giarratano(Istituto Oncologico Veneto), Mario Giuliano(Regione Campania), Rosa Giannatiempo, Marta Mion(University of Padua), Daniela Russo(University of Naples Federico II), Maria Vittoria Dieci(Istituto Oncologico Veneto), Paola Poletti(Ospedale Papa Giovanni XXIII), Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico), E. Rota Caremoli(Ospedale Papa Giovanni XXIII), Matteo Franchi(University of Milano-Bicocca)
Cited by 2
Related Papers
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials
|Journal of Clinical Oncology|2008|582